Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from ANVISA, Brazil, for two of its manufacturing facilities.
The certification covers the company's Oral Solid Dosage (OSD) unit, which manufactures medicines such as tablets and capsules, as well as its hormone manufacturing facility. Both facilities are located at Bhayla, Ahmedabad, Gujarat.
The company disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Corona Remedies Manufacturing and Regulatory Update
ANVISA is Brazil's health regulatory agency responsible for overseeing health-related products and services. Good Manufacturing Practice (GMP) requirements focus on maintaining appropriate manufacturing processes, product quality and quality control.
The certification adds to Corona Remedies' regulatory compliance record and may support its international business objectives. However, the company has not disclosed any specific export orders, additional revenue or immediate financial impact arising from this certification.
Corona Remedies ANVISA Certification Highlights
- Company: Corona Remedies Limited.
- Announcement: Receipt of GMP Compliance Certification.
- Regulatory authority: Brazilian Health Regulatory Agency (ANVISA).
- Certified facilities: Oral Solid Dosage (OSD) manufacturing unit and hormone manufacturing facility.
- Location: Bhayla, Ahmedabad, Gujarat.
- Disclosure date: October 22, 2026.
- Regulatory filing: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- BSE scrip code: 544644.
- NSE symbol: CORONA.
What to Watch Next
- Future announcements from Corona Remedies Limited may provide updates on export activities, international business development and regulatory approvals for individual pharmaceutical products.
- Further disclosures may clarify whether the certification leads to new business opportunities or contributes to the company's overseas operations.
- Subsequent stock exchange filings may also provide information on any commercial or financial impact associated with the certification.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Magellanic Cloud Subsidiary Emerges as L1 Bidder for Bank of Maharashtra Tender Worth Rs.115 Crore
Magellanic Cloud Limited has announced that its wholly owned subsidiary, Provigil Surveillance Limited, has emerged as the lowest bidder (L1) for a Bank of Maharashtra tender valued at approximately Rs.115 crore. The project involves deploying electronic surveillance systems across more than 1,550 bank sites, with the final contract award subject to the bank issuing a formal order.